Form 4 for PCVX Vaxcyte, Inc.
Accepted 2025-02-07 00:00:00 ET · period of report 2025-02-05 · accession 0001649094-25-000012 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-02-07 | 2025-02-05 | PCVX | Eydelman Mikhail | SVP, GEN COUNSEL, CORP SEC | S - Sale+OE | $90.07 | -5,000 | 30.3K | -14% | -$450.4K |
| D | 2025-02-07 | 2025-02-05 | PCVX | Eydelman Mikhail | SVP, GEN COUNSEL, CORP SEC | M - OptEx | $21.41 | +5,000 | 33.2K | +18% | +$107.0K |
| D | 2025-02-07 | 2025-02-05 | PCVX | Eydelman Mikhail | SVP, GEN COUNSEL, CORP SEC | M - OptEx | $0.00 | -5,000 | 149.5K | -3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-05 | S | D | 255 | $91.71 | 28,222 | D | — | — | (F6) The price reported is a weighted-average price. The shares were sold at prices ranging from $91.69 to $91.71. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 2 | Common | Common Stock | 2025-02-05 | S | D | 1,784 | $91.05 | 28,477 | D | — | — | (F5) The price reported is a weighted-average price. The shares were sold at prices ranging from $90.66 to $91.585. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 3 | Common | Common Stock | 2025-02-05 | S | D | 635 | $89.09 | 32,016 | D | — | — | (F3) The price reported is a weighted-average price. The shares were sold at prices ranging from $88.52 to $89.385. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 4 | Common | Common Stock | 2025-02-05 | S | D | 571 | $87.77 | 32,651 | D | — | — | (F2) The price reported is a weighted-average price. The shares were sold at prices ranging from $87.405 to $88.36. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 5 | Common | Common Stock | 2025-02-05 | M | A | 5,000 | $21.41 | 33,222 | D | — | — | |
| 6 | Common | Common Stock | 2025-02-05 | S | D | 1,755 | $89.95 | 30,261 | D | — | — | (F4) The price reported is a weighted-average price. The shares were sold at prices ranging from $89.53 to $90.50. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 7 | Derivative | Stock Option (right to buy) | 2025-02-05 | M | D | 5,000 | $0.00 | 149,497 | D | $21.41 · — to 2032-05-08 | 5,000 Common Stock | (F7) 1/4 of the shares subject to the option vested on April 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date. |